Stephen L. Huhn Insider Profile

4 Followers
Stephen L. Huhn, CMO & Sr VP, Clinical Dev at Contineum Therapeutics, Inc. Class A, holds 12.80K shares in Contineum Therapeutics, Inc. Class A (Ticker: CTNM).
tipranks
Stephen L. Huhn

Stephen L. Huhn
Contineum Therapeutics, Inc. Class A (CTNM)
CMO & Sr VP, Clinical Dev

Not Ranked
Stephen L. Huhn has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$245K
100.00%
A breakdown of Stephen L. Huhn's holdings

Insider Roles

Contineum Therapeutics, Inc. Class A
(CTNM)
CMO & Sr VP, Clinical Dev
Roles that Stephen L. Huhn holds in companies

Most Profitable Insider Trade

Currently, no data available
The most profitable trade made by Stephen L. Huhn

Stephen L. Huhn's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Contineum Therapeutics, Inc. Class A
Aug 14, 2024
CMO & Sr VP, Clinical Dev
Uninformative Buy
12.93K
$244.99K
Stephen L. Huhn has not reported any informative transactions for CTNM, therefore, performance cannot be measured.
Date
Transaction
Amount
No. of Shares
Price per Share
Profit
Link to Report
Aug 14, 2024
Uninformative Buy
$12.93K
-
$1.01
List of latest transactions for each holding click on a transaction to see Stephen L. Huhn's performance on stock

Stephen L. Huhn insider profile FAQ

What is the percentage of profitable transactions made by Stephen L. Huhn?
The percentage of profitable transactions made by Stephen L. Huhn is ―.
    What is the average return per transaction made by Stephen L. Huhn?
    The average return per transaction made by Stephen L. Huhn is ―.
      What stocks does Stephen L. Huhn hold?
      Stephen L. Huhn holds: CTNM stocks.
        What was Stephen L. Huhn’s latest transaction?
        Stephen L. Huhn latest transaction was an Uninformative Buy of $12.93K.
          What was Stephen L. Huhn's most profitable transaction?
          Stephen L. Huhn’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
            What is Stephen L. Huhn's role in Contineum Therapeutics, Inc. Class A?
            Stephen L. Huhn's role in Contineum Therapeutics, Inc. Class A is CMO & Sr VP, Clinical Dev.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.